Photo: Angiola Harry | Unsplash
Thousands of women facing advanced breast cancer in England and Wales are set to gain access to a much-anticipated new treatment — a twice-daily pill that could help slow the spread of the disease and offer precious time. The medication, called capivasertib or Truqap, has been approved for NHS use after the medicines watchdog, NICE (the National Institute for Health and Care Excellence), reversed its initial decision. Described by experts as a “landmark moment” for breast cancer care, the approval marks a significant step for women with hormone receptor (HR)-positive, HER2-negative breast cancer carrying certain genetic mutations — a group for whom treatment options have long been limited. Each year, around 3,000 women are expected to benefit from this targeted therapy. As the NHS moves forward with the rollout of capivasertib, advocates and experts alike hope the approval will not only extend lives but also set a precedent for faster access to innovative cancer treatments in the future.
|
|
More:
